Benzimidazole compound in crystal form and salt thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8471032
APP PUB NO 20110178128A1
SERIAL NO

13119242

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention aims to provide a stable form of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, which is free of problems of water adsorption and the like, and shows superior water solubility.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MITSUBISHI TANABE PHARMA CORPORATIONOSAKA-SHI OSAKA 541-8505

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Horiuchi, Hideki Osaka, JP 16 197
Ishige, Takayuki Osaka, JP 12 21
Minoguchi, Masanori Osaka, JP 12 128
Ono, Shinichirou Osaka, JP 3 14
Sekiguchi, Sumie Osaka, JP 4 179
Tanaka, Toshihiko Osaka, JP 219 2895

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 25, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00